Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e000095, January 1, 2025.

Cardiovascular Interventions 40

Cardiovascular Interventions Circulation 40

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014681, January 1, 2025.

Cardiovascular Interventions 40

Cardiovascular Interventions Outcomes Circulation 40

Circulation: Cardiovascular Interventions

MARCH 17, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 3 , Page e014819, March 1, 2025.

Bicuspid/Mitral 40

Bicuspid/Mitral Outcomes Heart Failure Cardiovascular Interventions 40

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014665, January 1, 2025. BACKGROUND:Bioresorbable scaffolds (BRS) were developed to overcome limitations related to late stent failures of drug-eluting stents, but lumen reductions over time after implantation of BRS have been reported.

Stenosis 40

Stenosis Ultrasound Stents Stent 40

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014499, January 1, 2025. BACKGROUND:The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).METHODS:This

Embolism 40

Embolism Pulmonary Outcomes Cardiac Arrest 40

DAIC

APRIL 5, 2024

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need. in 2024 and approximately $0.17

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

DAIC

MAY 31, 2024

This transaction further extends Johnson & Johnson MedTech’s leadership in cardiovascular intervention. We are excited to begin collaborating directly with the Shockwave team and look forward to a bright future together.” The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

DAIC

FEBRUARY 14, 2025

Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb. 10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio.

Peripheral Arterial Disease 52

Peripheral Arterial Disease Cancer Innovation Best Practices 52

Circulation: Cardiovascular Interventions

MARCH 17, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 3 , Page e014899, March 1, 2025. BACKGROUND:Ineligibility for surgical revascularization is increasingly prevalent and associated with increased mortality after percutaneous coronary intervention (PCI).

Coronary Artery Disease 40

Coronary Artery Disease Outcomes Myocardial Infarction Cardiovascular Interventions 40

Circulation: Cardiovascular Interventions

JANUARY 20, 2025

Circulation: Cardiovascular Interventions, Volume 18, Issue 1 , Page e014592, January 1, 2025. Therefore, it is critically important to understand the validity of these claims-based end points.

Aortic valve 40

Aortic valve Outcomes Pacemaker Aortic 40

DAIC

FEBRUARY 14, 2025

Lorraine and Bill Dodero tim.hodson Fri, 02/14/2025 - 15:33 Feb. 10, 2025 A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio.

Hospital 52

Hospital Peripheral Arterial Disease Cancer Innovation 52

Dr. Smith's ECG Blog

JANUARY 24, 2025

J Cardiovascular Interventions.--20/53 This is why you should never wait for troponin to reperfuse when the ECG says "OMI [link] == MY Comment, by K EN G RAUER, MD ( 1/21/2025 ): == Todays case is frustrating because there is no way that 30 hours should have passed until cardiac cath was done.

Chest Pain 123

Chest Pain STEMI Risk Factors Coronary Artery Disease 123

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Lancet Commission on Obesity: The Lancet Diabetes & Endocrinology journal has accepted the Lancet Commission on Obesity’s report for publication, scheduled for early 2025, announced Robert H. Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

Dr. Smith's ECG Blog

MARCH 17, 2025

Summary of RIDDLE-NSTEMI: RIDDLE-NSTEMI, JACC: Cardiovascular Interventions 2016 Limitations of conventional angiography: This patient was very lucky that the interventional cardiologist who responded to the cath lab activation is evidence based and thorough.

STEMI 80

STEMI Chest Pain Myocardial Infarction Document 80

DAIC

MARCH 17, 2025

tim.hodson Mon, 03/17/2025 - 11:30 March 17, 2025 GE HealthCare recently launchedthe AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. AltiX AI.i

Document 59

Document Coronary Artery Disease Innovation Cardiovascular Disease 59

Dr. Smith's ECG Blog

MARCH 8, 2025

Catheterization and Cardiovascular Interventions , 82 (6), 909913. Learning points: Takotsubo and OMI can co-exist If max output on the defibrillator doesn't terminate VT, add another defibrillator If amiodarone, lidocaine, and magnesium are ineffective at suppressing VT/VF, consider VA ECMO or propranolol References: AnguloLlanos, R.,

Cardiomyopathy 74

Cardiomyopathy Myocardial Infarction Defibrillator Bradycardia 74